Filing Flows › Halozyme Therapeutics (HALO) › Royalties revenue
Halozyme Therapeutics (HALO) Royalties revenue by quarter
Halozyme Therapeutics' Royalties revenue was $341M in Q3 2026 (third quarter 2026), +11% from Q2 2026. Over the last 7 quarters it ranged from $168M (Q1 2025) to $341M (Q3 2026).
| Quarter | Royalties revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $341M | +11% | +44% |
| Q2 2026 | $308M | +28% | +50% |
| Q1 2026 | $241M | -7% | +43% |
| Q4 2025 | $258M | +9% | — |
| Q3 2025 | $236M | +15% | — |
| Q2 2025 | $206M | +22% | — |
| Q1 2025 | $168M | — | — |
Q3 2026 at a glance
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
Questions
What is Halozyme Therapeutics' Royalties revenue?
Halozyme Therapeutics' Royalties revenue was $341M in Q3 2026 (third quarter 2026), +11% from Q2 2026.
How has Halozyme Therapeutics' Royalties revenue changed?
Over the last 7 quarters it ranged from $168M (Q1 2025) to $341M (Q3 2026).